Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications
July 20 2020 - 10:00AM
Vyriad, Inc. announced today the dosing of the first patient in a
Phase 2 clinical trial to evaluate its investigational oncolytic
virus Voyager-V1 in combination with the PD-1 inhibitor Libtayo®
(cemiplimab) in four difficult-to-treat or refractory advanced
stage cancers. Libtayo is being jointly developed and
commercialized by Regeneron and Sanofi under a global collaboration
agreement.
The open-label study will enroll up to an estimated 152 patients
with non-small cell lung cancer or melanoma who have progressed on
checkpoint inhibitor treatment and patients with hepatocellular
carcinoma or endometrial cancer. The study will evaluate overall
patient responses to the treatment, as well as safety,
tolerability, pharmacodynamic and pharmacokinetic data. For
additional information about the study, please visit
www.clinicaltrials.gov (search identifier NCT04291105).
Voyager-V1 is an engineered vesicular stomatitis virus
programmed to target, infect and kill cancer cells, while
activating immune system responses that may enhance the restoration
of antitumor T cell response by Libtayo.
“We are optimistic that this therapeutic combination will
meaningfully increase the treatment responses of cancer patients
with high unmet clinical needs,” said Stephen Russell, M.D., Ph.D.,
Vyriad President and Chief Executive Officer. “We are pleased
the study has commenced and we look forward to the results.”
“The promise of cancer immunotherapies has yet to be fulfilled
as evidenced by their limited effectiveness in many patient
groups,“ said Steven Powell, M.D., a medical oncologist who is the
study’s principal investigator at Sanford Health, which treated the
first patient in the study. “We’re excited to evaluate this
therapy, which combines a systemically active oncolytic with an
effective immunotherapy. We hope that this combination approach may
turn cold tumors hot and facilitate clinically meaningful
anti-cancer immune responses in multiple cancer types.”
Libtayo was invented by Regeneron using the company's
proprietary VelocImmune® technology which uses a unique
genetically-humanized mouse to produce optimized fully-human
antibodies.
About Vyriad, Inc.Vyriad is a clinical-stage
company developing virus-based therapeutics, focusing initially on
proprietary oncolytic virus therapies for the treatment of cancers
with significant unmet needs. Founded by scientists at Mayo Clinic
and the University of Miami, Vyriad programs viruses to selectively
attack cancer cells, thereby igniting antitumor immune responses
that can complete the process of tumor destruction and prevent
disease recurrence. Our lead platforms, derived from either
vesicular stomatitis virus or measles virus (VSV), are being
evaluated in ongoing Phase 2 clinical trials addressing multiple
cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN) have entered into a broad strategic agreement for the
discovery and development of new oncolytic virus treatments for
cancer leveraging Vyriad’s VSV platform and Regeneron’s PD-1
inhibitor Libtayo® (cemiplimab) as well as its unmatched antibody
discovery capabilities. Vyriad is a privately held company based in
Rochester, Minnesota. For more information, visit
www.vyriad.com.
Contacts:
Media RelationsDavid Walsh(651)
503-8248dwalsh@vyriad.com |
Investor RelationsBarb Duckett(507)
289-0944bduckett@vyriad.com |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024